Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 639-644

  Tsunoka, Tomoko ^a   Kishi, Taro ^a   Kitajima, Tsuyoshi ^a   Okochi, Tomo ^a   Okumura, Takenori ^a   Yamanouchi, Yoshio ^a   Kinoshita, Yoko ^a   Kawashima, Kunihiro ^a   Naitoh, Hiroshi ^a   Inada, Toshiya ^b,c   Ujike, Hiroshi ^b,d   Yamada, Mitsuhiko ^b,e   Uchimura, Naohisa ^b,f   Sora, Ichiro ^b,g   Iyo, Masaomi ^b,h   Ozaki, Norio ^b,i   Iwata, Nakao ^a,b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Japanese Genetics Initiative for Drug Abuse ^*  (Japan)

^c SEIWA HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Functional SNP; Glutamate metabotropic receptor 2 gene (GRM2); Methamphetamine induced psychosis; Schizophrenia; Serotonin receptor 2A gene (HTR2A); Tagging SNP

Indexed keywords

DNA; METABOTROPIC RECEPTOR 2; METHAMPHETAMINE; SEROTONIN 2A RECEPTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NEUROTRANSMISSION; PATHOGENESIS; POPULATION GENETICS; PSYCHOSIS; SAMPLE SIZE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AMPHETAMINE-RELATED DISORDERS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; JAPAN; METHAMPHETAMINE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 77952671499     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.002     Document Type: Article

References (60)

1. Abdolmaleky H.M., Faraone S.V., Glatt S.J., Tsuang M.T. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004, 67:53-62.
2. Badner J.A., Gershon E.S. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002, 7:405-411.
3. Baritaki S., Rizos E., Zafiropoulos A., Soufla G., Katsafouros K., Gourvas V., et al. Association between schizophrenia and DRD3 or HTR2 receptor gene variants. Eur J Hum Genet 2004, 12:535-541.
4. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Basile V.S., Masellis M., McIntyre R.S., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001, 62(Suppl 23):45-66.
6. Bousman C.A., Glatt S.J., Everall I.P., Tsuang M.T. Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:1025-1049.
7. Chakravarti A. Population genetics-making sense out of sequence. Nat Genet 1999, 21:56-60.
8. Chen X, Cho K, Singer BH, Zhang H. PKNOX2 gene is significantly associatedwith substance dependence in European-origin women. Proc Natl Acad Sci U S A in press.
9. Dominguez E., Loza M.I., Padin F., Gesteira A., Paz E., Paramo M., et al. Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population. Schizophr Res 2007, 90:123-129.
10. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25:115-121.
11. Ertugrul A., Kennedy J.L., Masellis M., Basile V.S., Jayathilake K., Meltzer H.Y. No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophr Res 2004, 69:301-305.
12. Golimbet V.E., Lavrushina O.M., Kaleda V.G., Abramova L.I., Lezheiko T.V. Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study. Eur Psychiatry 2007, 22:167-170.
13. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
14. Hahn L.W., Ritchie M.D., Moore J.H. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003, 19:376-382.
15. Holmans P.A., Riley B., Pulver A.E., Owen M.J., Wildenauer D.B., Gejman P.V., et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 2009, 14:786-795.
16. Hovatta I., Lichtermann D., Juvonen H., Suvisaari J., Terwilliger J.D., Arajarvi R., et al. Linkage analysis of putative schizophrenia gene candidate regions on chromosomes 3p, 5q, 6p, 8p, 20p and 22q in a population-based sampled Finnish family set. Mol Psychiatry 1998, 3:452-457.
17. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry 2004, 56:698-700.
18. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshiya Y., et al. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int J Neuropsychopharmacol 2006, 9:77-81.
19. Ikeda M., Aleksic B., Kirov G., Kinoshita Y., Yamanouchi Y., Kitajima T., et al. Copy number variation in schizophrenia in the Japanese population. Biol Psychiatry 2010, 67:283-286.
20. Inayama Y., Yoneda H., Sakai T., Ishida T., Nonomura Y., Kono Y., et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996, 67:103-105.
21. Joo A., Shibata H., Ninomiya H., Kawasaki H., Tashiro N., Fukumaki Y. Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. Mol Psychiatry 2001, 6:186-192.
22. Kirov G., Zaharieva I., Georgieva L., Moskvina V., Nikolov I., Cichon S., et al. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry 2009, 14:796-803.
23. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., et al. Alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. Ann N Y Acad Sci 2008, 1139:70-82.
24. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., et al. A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:895-898.
25. Kishi T., Kitajima T., Tsunoka T., Ikeda M., Yamanouchi Y., Kinoshita Y., et al. Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neurosci Res 2009, 64:231-234.
26. Kishi T., Tsunoka T., Ikeda M., Kitajima T., Kawashima K., Okochi T., et al. Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology 2010, 58:452-456.
27. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med in press.
28. Kishimoto M., Ujike H., Motohashi Y., Tanaka Y., Okahisa Y., Kotaka T., et al. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry 2008, 63:191-196.
29. Kishimoto M., Ujike H., Okahisa Y., Kotaka T., Takaki M., Kodama M., et al. The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population. Behav Brain Funct 2008, 4:37.
30. Kotaka T., Ujike H., Okahisa Y., Takaki M., Nakata K., Kodama M., et al. G72 gene is associated with susceptibility to methamphetamine psychosis. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1046-1049.
31. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003, 73:34-48.
32. Maziade M., Roy M.A., Rouillard E., Bissonnette L., Fournier J.P., Roy A., et al. A search for specific and common susceptibility loci for schizophrenia and bipolar disorder: a linkage study in 13 target chromosomes. Mol Psychiatry 2001, 6:684-693.
33. Morita Y., Ujike H., Tanaka Y., Kishimoto M., Okahisa Y., Kotaka T., et al. The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:54-58.
34. Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., et al. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 2009, 14:252-260.
35. Myers R.L., Airey D.C., Manier D.H., Shelton R.C., Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry 2007, 61:167-173.
36. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008, 40:1053-1055.
37. O'Donovan M.C., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., et al. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol Psychiatry 2009, 14:30-36.
38. Otani K., Ujike H., Sakai A., Okahisa Y., Kotaka T., Inada T., et al. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci Lett 2008, 434:88-92.
39. Pae C.U., Artioli P., Serretti A., Kim T.S., Kim J.J., Lee C.U., et al. No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. Neurosci Res 2005, 52:195-199.
40. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
41. Pulver A.E., Lasseter V.K., Kasch L., Wolyniec P., Nestadt G., Blouin J.L., et al. Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet 1995, 60:252-260.
42. Purcell S., Cherny S.S., Sham P.C. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
43. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
44. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
45. Sanders A.R., Duan J., Levinson D.F., Shi J., He D., Hou C., et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 2008, 165:497-506.
46. Sato M., Chen C.C., Akiyama K., Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983, 18:429-440.
47. Sato M., Numachi Y., Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992, 18:115-122.
48. Satow A., Maehara S., Ise S., Hikichi H., Fukushima M., Suzuki G., et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J Pharmacol Exp Ther 2008, 326:577-586.
49. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry 1973, 130:61-67.
50. Snyder S.H. Neuroscience: a complex in psychosis. Nature 2008, 452:38-39.
51. Spurlock G., Heils A., Holmans P., Williams J., D'Souza U.M., Cardno A., et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998, 3:42-49.
52. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
53. Suzuki T., Iwata N., Kitamura Y., Kitajima T., Yamanouchi Y., Ikeda M., et al. Association of a haplotype in the serotonin 5-HT4 receptor gene (HTR4) with Japanese schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003, 121B:7-13.
54. Tsunoka T., Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. Association analysis of Group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:875-879.
55. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 2002, 4:177-184.
56. Ujike H., Katsu T., Okahisa Y., Takaki M., Kodama M., Inada T., et al. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:625-629.
57. Weickert C.S., Miranda-Angulo A.L., Wong J., Perlman W.R., Ward S.E., Radhakrishna V., et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet 2008, 17:2293-2309.
58. Weinberger D.R. Schizophrenia drug says goodbye to dopamine. Nat Med 2007, 13:1018-1019.
59. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196:431-440.
60. Zhang X.N., Jiang S.D., He X.H., Zhang L.N. 102T/C SNP in the 5-hydroxytryptamine receptor 2A (HTR2A) gene and schizophrenia in two southern Han Chinese populations: lack of association. Am J Med Genet B Neuropsychiatr Genet 2004, 126B:16-18.